Related Experiment Video
Updated: Apr 16, 2026
09:02
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
3.3K
Temozolomide nanoparticles for targeted glioblastoma therapy
Chen Fang1,2, Kui Wang2, Zachary R Stephen2
1†Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, United States.
ACS Applied Materials & Interfaces
|March 10, 2015
Summary
Researchers developed nanoparticle carriers to protect Temozolomide (TMZ) from degradation and target glioblastoma (GBM) cells. This novel approach enhances drug stability and delivery for improved brain tumor treatment.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with poor patient outcomes.
- Standard treatments like surgery, radiation, and Temozolomide (TMZ) chemotherapy face challenges due to TMZ's rapid degradation and poor tumor targeting.
- Ineffective drug delivery and systemic toxicity limit current GBM therapies.
Purpose of the Study:
- To develop a nanoparticle-based drug delivery system for enhanced stability and targeted delivery of Temozolomide (TMZ) to glioblastoma (GBM) cells.
- To overcome the limitations of rapid drug degradation and non-specific distribution associated with conventional TMZ chemotherapy.
- To create a nanoparticle carrier (NP-TMZ-CTX) functionalized with chlorotoxin (CTX) for specific GBM cell targeting.
Main Methods:
- Synthesized nanoparticle carriers (<100 nm) designed to encapsulate and protect TMZ.
- Functionalized nanoparticles with chlorotoxin (CTX) to mediate targeted delivery to GBM cells.
- Evaluated nanoparticle stability in physiological conditions and drug loading capacity.
- Assessed nanoparticle uptake, stability, and therapeutic efficacy (IC50) in GBM cells compared to non-targeted nanoparticles.
Main Results:
- Nanoparticles demonstrated sustained stability in cell culture media for up to 2 weeks.
- TMZ-loaded nanoparticles exhibited a 7-fold increase in half-life at physiological pH compared to free TMZ.
- NP-TMZ-CTX showed 2-6 fold higher uptake in GBM cells and a 50-90% reduction in IC50.
- The targeted nanoparticles effectively delivered therapeutic doses of TMZ to GBM cells.
Conclusions:
- The developed nanoparticle system (NP-TMZ-CTX) effectively protects TMZ from degradation and enhances its targeted delivery to GBM cells.
- This targeted delivery approach significantly improves the therapeutic efficacy of TMZ against glioblastoma.
- NP-TMZ-CTX holds promise as a novel platform for targeted glioblastoma therapy and potentially for other therapeutics.
